Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
Top Cited Papers
- 1 November 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 3 (11), 1451-1461
- https://doi.org/10.1158/1940-6207.capr-10-0157
Abstract
Metformin, an insulin-lowering agent, has been associated with decreased cancer risk in epidemiologic studies in diabetic patients. We performed a comprehensive literature search and meta-analysis of epidemiologic studies to assess the effect of metformin on cancer incidence and mortality in diabetic patients, using Pubmed, ISI Web of Science, Embase, and the Cochrane library until May 2009, with no language or time restrictions. Independent reports with sufficient information to allow risk estimation of cancer risk/mortality and a measure of uncertainty were reviewed and cross-checked independently by three investigators. Eleven studies were selected for relevance in terms of intervention, population studied, independence, and reporting of cancer incidence or mortality data, reporting 4,042 cancer events and 529 cancer deaths. A 31% reduction in overall summary relative risk (0.69; 95% confidence interval, 0.61-0.79) was found in subjects taking metformin compared with other antidiabetic drugs. The inverse association was significant for pancreatic and hepatocellular cancer, and nonsignificant for colon, breast, and prostate cancer. A trend to a dose-response relationship was noted. Metformin is associated with a decreased risk of cancer incidence compared with other treatments among diabetic patients. Given the retrospective nature of most studies and the possibility that the control treatments increase risk, phase II trials are needed before large cancer prevention trials are launched. Cancer Prev Res; 3(11); 1451–61. ©2010 AACR.Keywords
This publication has 73 references indexed in Scilit:
- Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: A nested case–control studyNutrition, Metabolism and Cardiovascular Diseases, 2010
- 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyThe Lancet, 2009
- Epidemiology of pancreatic cancer: an overviewNature Reviews Gastroenterology & Hepatology, 2009
- Metformin use and prostate cancer in Caucasian men: results from a population-based case–control studyCancer Causes & Control, 2009
- Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label studyDiabetologia, 2009
- Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology GroupDiabetologia, 2009
- Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort studyDiabetologia, 2009
- Cardiovascular Outcomes in Trials of Oral Diabetes Medications - A Systematic ReviewArchives of Internal Medicine, 2008
- The Role of Obesity and Related Metabolic Disturbances in Cancers of the Colon, Prostate, and PancreasGastroenterology, 2007
- Insulin-like growth factors and neoplasiaNature Reviews Cancer, 2004